AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02444351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle
Description: ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
Study NCT02444351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: Patients in the control group will not receive any injection on the gastrocnemius muscle.
Study NCT03412578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage Therapy
Description: Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
Study NCT01437813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/ Extended release Metformin
Description: One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
Study NCT00064428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux - UFH not indicated
Description: 2.5mg od, sc (1st dose IV) x 8 days or discharge
Study NCT00064428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - UFH not indicated
Description: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
Study NCT00064428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux - UFH indicated
Description: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
Study NCT00064428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control - UFH
Description: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
Study NCT00706914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily aclidinium/formoterol
Description: Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
Study NCT00706914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily formoterol fumarate
Description: Inhaled formoterol fumarate 12 µg twice-daily (BID)
Study NCT00706914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to formoterol fumarate
Description: Inhaled placebo to formoterol fumarate once-daily in the evening
Study NCT00706914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-daily formoterol fumarate
Description: Inhaled formoterol fumarate 12 μg once-daily in the evening
Study NCT03535480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF subcutaneously during five days
Study NCT03535480 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ASCOT
Description: G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuresis (furosemide) part I
Description: Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuresis (furosemide) part I
Description: Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period
Study NCT00624650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Bolus (crystalloid or albumin)
Description: 15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP\<8 or measured PaOP \<12mmHg in addition to concurrent urine output of \<0.5 ml/kg/hr
Study NCT00624650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Bolus (crystalloid or albumin)
Description: 10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map \< 60 or who are on vasopressors that also have a measured GEDI less than goal
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
Description: (may use any alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)
Description: (may use alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of \< 60
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: 1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index \< 2.5
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: 1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.
Study NCT00624650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrate all drips and nutrition
Description: Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal.
Study NCT01805609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT03845309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Behavior
Description: Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
Study NCT00772564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral Atorvastatin
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuresis (furosemide) part II
Description: Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases > 1.5 mg/dl in any 24 hour period
Study NCT00624650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuresis (furosemide) part II
Description: Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases > 1.5 mg/dl in any 24 hour period
Study NCT00624650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: 1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm.
Study NCT00624650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis
Description: 1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm.
Study NCT00006994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glutamine
Description: 20 cc three times daily for 60 days
Study NCT00006994 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
Study NCT00006994 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
Study NCT00006994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: l-glutamine placebo
Description: 20 cc three times daily for 60 days
Study NCT00770133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen/naphazoline
Description: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
Study NCT00770133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naphazoline
Description: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
Study NCT01717547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based treatment
Study NCT03505255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
Study NCT00770133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
Study NCT00770133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: One drop of vehicle ophthalmic solution at visit 3 and visit 4.
Study NCT00455520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG5503
Description: 100, 150, 200, 250 mg twice daily given for up to 15 weeks
Study NCT00455520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo twice daily for 12 weeks
Study NCT01733459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: 1 DLBS3233 capsule 100 mg once daily for 6 months
Study NCT01733459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: 1 Metformin XR caplet 750 mg twice daily for 6 months
Study NCT01733459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo caplet of Metformin XR
Description: 1 placebo caplet of Metformin XR twice daily for 6 months
Study NCT01733459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule of DLBS3233
Description: 1 placebo capsule of DLBS3233 once daily for 6 months
Study NCT03505255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 0.9 % is given in the control group
Study NCT01490359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men Making a Difference HIV/STD Risk Reduction Intervention
Description: Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
Study NCT01490359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Control
Description: The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
Study NCT03372577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Sex Therapy
Description: It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
Study NCT03372577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Routine discharge counseling
Study NCT01179906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
Study NCT01179906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet modification
Description: Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
Study NCT02210169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of vancomycin
Description: Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
Study NCT03617861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Secretin
Description: Injected once over one minute
Study NCT03617861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injected once over one minute
Study NCT03716947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: ZACK
Description: Surgical procedure with total disc replacement using ZACK disc prostheses
Study NCT03716947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: ORBIT
Description: Surgical procedure with total disc replacement using ORBIT disc prostheses
Study NCT03716947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: SASCA
Description: Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
Study NCT03716947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: SASCA
Description: Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
Study NCT02396758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekosonic® Endovascular Device ultrasonic infusion catheter
Description: r-tPA will be administered via EKOS.
Study NCT02396758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Description: Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
Study NCT03220776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg
Study NCT03220776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetylcysteine
Description: 5 day trial of N-acetylcysteine with titration to 2,400mg
Study NCT03220776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg
Study NCT03220776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: 5 day trial of gabapentin with titration to 1,200mg
Study NCT03220776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo
Study NCT03220776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 5 day trial of matched placebo
Study NCT01780545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity.
Study NCT01780545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles.
Study NCT01780545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles.